{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:05:42Z","timestamp":1761894342670,"version":"build-2065373602"},"reference-count":43,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Aging Pathology"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1016\/j.biomag.2014.03.003","type":"journal-article","created":{"date-parts":[[2014,4,24]],"date-time":"2014-04-24T05:56:49Z","timestamp":1398319009000},"page":"169-178","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Treatment of muscle invasive urinary bladders tumors: A potential role of the mTOR inhibitors"],"prefix":"10.1016","volume":"4","author":[{"given":"Ros\u00e1rio","family":"Pinto-Leite","sequence":"first","affiliation":[]},{"given":"Regina","family":"Arantes-Rodrigues","sequence":"additional","affiliation":[]},{"given":"Rita","family":"Ferreira","sequence":"additional","affiliation":[]},{"given":"Carlos","family":"Palmeira","sequence":"additional","affiliation":[]},{"given":"Paula A.","family":"Oliveira","sequence":"additional","affiliation":[]},{"given":"L\u00facio","family":"Santos","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/j.biomag.2014.03.003_bib0005","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/cncr.27763","article-title":"Combination of molecular alterations and smoking intensity predicts bladder cancer outcome: a report from the Los Angeles Cancer Surveillance Program","volume":"119","author":"Mitra","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.biomag.2014.03.003_bib0010","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.eururo.2013.03.032","article-title":"European guidelines on upper tract urothelial carcinomas: 2013 update","volume":"63","author":"Roupr\u00eat","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.biomag.2014.03.003_bib0015","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1741-7015-11-13","article-title":"Recent advances in the diagnosis and treatment of bladder cancer","volume":"1","author":"Cheung","year":"2013","journal-title":"BMC Med"},{"key":"10.1016\/j.biomag.2014.03.003_bib0020","doi-asserted-by":"crossref","first-page":"424","DOI":"10.4103\/0970-1591.105756","article-title":"Neoadjuvant and adjuvant chemotherapy for muscle invasive bladder cancer: the likelihood of initiation and completion","volume":"28","author":"Eldefrawy","year":"2012","journal-title":"Indian J Urol"},{"key":"10.1016\/j.biomag.2014.03.003_bib0025","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1756-8722-4-35","article-title":"Chemotherapy in advanced bladder cancer: current status and future","volume":"4","author":"Ismaili","year":"2011","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.biomag.2014.03.003_bib0030","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s11934-012-0238-0","article-title":"Recent advances in treatment of advanced urothelial carcinoma","volume":"2012","author":"Kim","year":"2012","journal-title":"Curr Urol Rep"},{"key":"10.1016\/j.biomag.2014.03.003_bib0035","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.eururo.2013.11.046","article-title":"EUA Guidelines on muscle invasive and metastatic bladder cancer: summary of the 2013 Guidelines","volume":"65","author":"Witjes","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.biomag.2014.03.003_bib0040","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1007\/s11912-010-0104-5","article-title":"Bladder cancer: can we move beyond chemotherapy?","volume":"12","author":"Siefker-Radtke","year":"2010","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.biomag.2014.03.003_bib0045","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.ejca.2012.01.022","article-title":"Accelerated MVAC chemotherapy in patients with advanced urinary bladder cancer previously treated with a platinum-gemcitabine regimen","volume":"48","author":"Edeline","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.biomag.2014.03.003_bib0050","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.3390\/toxins2112490","article-title":"Mechanisms of cisplatin nephrotoxicity","volume":"2","author":"Miller","year":"2012","journal-title":"Reeves Toxins"},{"key":"10.1016\/j.biomag.2014.03.003_bib0055","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1038\/labinvest.2010.133","article-title":"Expanding therapeutic targets in bladder cancer: the PI3K\/Akt\/mTOR pathway","volume":"90","author":"Ching","year":"2010","journal-title":"Lab Invest"},{"key":"10.1016\/j.biomag.2014.03.003_bib0060","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1111\/j.1365-2559.2011.03856.x","article-title":"Activation of the PI3K\/Akt\/mTOR pathway correlates with tumor progression and reduced survival in patients with urothelial carcinoma of the urinary bladder","volume":"58","author":"Sun","year":"2011","journal-title":"Histopathology"},{"key":"10.1016\/j.biomag.2014.03.003_bib0065","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ctrv.2008.09.006","article-title":"The role of mTOR in the management of solid tumors: an overview","volume":"35","author":"Strimpakos","year":"2009","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.biomag.2014.03.003_bib0070","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1158\/1535-7163.MCT-07-2408","article-title":"Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies","volume":"27","author":"Garcia","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.biomag.2014.03.003_bib0075","doi-asserted-by":"crossref","first-page":"435342","DOI":"10.1155\/2012\/435342","article-title":"The role of mTOR inhibitors for the treatment of B-cell lymphomas","volume":"2012","author":"Argyriou","year":"2012","journal-title":"Adv Hematol"},{"key":"10.1016\/j.biomag.2014.03.003_bib0080","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.biopha.2012.11.007","article-title":"Everolimus combined with cisplatin has a potential role in treatment of urothelial bladder cancer","volume":"67","author":"Pinto-Leite","year":"2013","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.biomag.2014.03.003_bib0085","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1080\/15287394.2012.690325","article-title":"Everolimus enhances gemcitabine-induced cytotoxicity in bladder cancer cell lines","volume":"75","author":"Pinto-Leite","year":"2012","journal-title":"J Toxicol Environ Health A"},{"key":"10.1016\/j.biomag.2014.03.003_bib0090","first-page":"41","article-title":"Temsirolimus improves cytotoxic efficacy of cisplatin and gemcitabine against urinary bladder cancer cell lines","volume":"32","author":"Pinto-Leite","year":"2013","journal-title":"Urol Oncol"},{"key":"10.1016\/j.biomag.2014.03.003_bib0095","article-title":"Comprehensive molecular characterization of urothelial bladder carcinoma","author":"The Cancer Genome Atlas Research Network","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.biomag.2014.03.003_bib0100","doi-asserted-by":"crossref","DOI":"10.1007\/s13277-013-1604-3","article-title":"Genomic characterization of three urinary bladder cancer cell lines: understanding genomic types of urinary bladder cancer","author":"Pinto-Leite","year":"2014","journal-title":"Tumour Biol"},{"key":"10.1016\/j.biomag.2014.03.003_bib0105","doi-asserted-by":"crossref","first-page":"791406","DOI":"10.1155\/2013\/791406","article-title":"Synergistic effect between cisplatin and sunitinib malate on human urinary bladder cancer cell lines","volume":"2013","author":"Arantes-Rodrigues","year":"2013","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.biomag.2014.03.003_bib0110","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.critrevonc.2013.08.008","article-title":"Biomarkers in bladder cancer: translational and clinical implications","volume":"89","author":"Cheng","year":"2013","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.biomag.2014.03.003_bib0115","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.biopha.2013.01.010","article-title":"Meloxicam in the treatment of in vitro and in vivo models of urinary bladder cancer","volume":"67","author":"Arantes-Rodrigues","year":"2013","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.biomag.2014.03.003_bib0120","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.urolonc.2011.11.002","article-title":"In vivo and in vitro effects of RAD001 on bladder cancer","volume":"31","author":"Vasconcelos-N\u00f3brega","year":"2013","journal-title":"Urol Oncol"},{"key":"10.1016\/j.biomag.2014.03.003_bib0125","doi-asserted-by":"crossref","first-page":"372","DOI":"10.5858\/arpa.2011-0471-RA","article-title":"Emerging critical role of molecular testing in diagnostic genitourinary pathology","volume":"136","author":"Netto","year":"2012","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.biomag.2014.03.003_bib0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2012.12.015","article-title":"Differentiating mTOR inhibitors in renal cell carcinoma","author":"Pal","year":"2013","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.biomag.2014.03.003_bib0135","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.3109\/10428190903207548","article-title":"Exploring mammalian target of rapamycin (mTOR) inhibition for treatment of mantle cell lymphoma and other hematologic malignancies","volume":"50","author":"Coiffier","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.biomag.2014.03.003_bib0140","doi-asserted-by":"crossref","first-page":"214","DOI":"10.2174\/157488411797189433","article-title":"Therapeutic rationale for mTOR inhibition in advanced renal cell carcinoma","volume":"6","author":"Husseinzadeh","year":"2011","journal-title":"Curr Clin Pharmacol"},{"key":"10.1016\/j.biomag.2014.03.003_bib0145","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/nrd3531","article-title":"Rapamycin passes the torch: a new generation of mTOR inhibitors","volume":"10","author":"Benjamin","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.biomag.2014.03.003_bib0150","doi-asserted-by":"crossref","first-page":"466","DOI":"10.4111\/kju.2011.52.7.466","article-title":"Role of the mTOR pathway in the progression and recurrence of bladder cancer: an immunohistochemical tissue microarray study","volume":"52","author":"Park","year":"2011","journal-title":"Korean J Urol"},{"key":"10.1016\/j.biomag.2014.03.003_bib0155","first-page":"3065","article-title":"Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer","volume":"118","author":"Carracedo","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1016\/j.biomag.2014.03.003_bib0160","doi-asserted-by":"crossref","first-page":"35375","DOI":"10.1074\/jbc.M806480200","article-title":"S6K directly phosphorylates IRS-1 on Ser-270 to promote insulin resistance in response to TNF-(alpha) signaling through IKK2","volume":"283","author":"Zhang","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.biomag.2014.03.003_bib0165","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1016\/j.humpath.2012.11.026","article-title":"Relevance of the mammalian target of rapamycin pathway in the prognosis of patients with high-risk non-muscle invasive bladder cancer","volume":"44","author":"Fahmy","year":"2013","journal-title":"Hum Pathol"},{"key":"10.1016\/j.biomag.2014.03.003_bib0170","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1200\/JCO.2008.20.0766","article-title":"Targeting the mTOR signaling network for cancer therapy","volume":"27","author":"Meric-Bernstam","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.biomag.2014.03.003_bib0175","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1158\/1078-0432.CCR-09-3202","article-title":"Effects of mTOR inhibitor everolimus (RAD001) on bladder cancer cells","volume":"17","author":"Chiong","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.biomag.2014.03.003_bib0180","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1158\/0008-5472.CAN-12-3923","article-title":"Everolimus in advanced pancreatic neuroendocrine tumors: the clinical experience","volume":"73","author":"Yao","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.biomag.2014.03.003_bib0185","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1158\/0008-5472.CAN-07-6487","article-title":"A new pharmacologic action of CCI-779 involves FKBP12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis","volume":"68","author":"Shor","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.biomag.2014.03.003_bib0190","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.2353\/ajpath.2010.090872","article-title":"Mammalian target of rapamycin (mTOR) regulates cellular proliferation and tumor growth in urothelial carcinoma","volume":"176","author":"Hansel","year":"2010","journal-title":"Am J Pathol"},{"key":"10.1016\/j.biomag.2014.03.003_bib0195","doi-asserted-by":"crossref","first-page":"963","DOI":"10.3109\/0284186X.2013.776175","article-title":"Phase II trial of temsirolimus alone and in combination with irinotecan for KRAS mutant metastatic colorectal cancer: outcome and results of KRAS mutational analysis in plasma","volume":"52","author":"Spindler","year":"2013","journal-title":"Acta Oncol"},{"key":"10.1016\/j.biomag.2014.03.003_bib0200","doi-asserted-by":"crossref","first-page":"103830","DOI":"10.1155\/2013\/103830","article-title":"Enhanced antitumor activity with combining effect of mTOR inhibition and microtubule stabilization in hepatocellular carcinoma","volume":"2013","author":"Zhou","year":"2013","journal-title":"Int J Hepatol"},{"key":"10.1016\/j.biomag.2014.03.003_bib0205","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.urolonc.2010.04.003","article-title":"Bladder cancer or bladder cancers? Genetically distinct malignant conditions of the urothelium","volume":"28","author":"Goebell","year":"2010","journal-title":"Urol Oncol"},{"key":"10.1016\/j.biomag.2014.03.003_bib0210","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrurol.2011.193","article-title":"Molecular biomarkers in urothelial carcinoma of the bladder: are we there yet?","volume":"9","author":"Netto","year":"2011","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.biomag.2014.03.003_bib0215","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1475-2867-13-11","article-title":"Targeted inhibition of heat shock protein 90 disrupts multiple oncogenic signaling pathways, thus inducing cell cycle arrest and programmed cell death in human urinary bladder cancer cell lines","volume":"13","author":"Karkoulis","year":"2013","journal-title":"Cancer Cell Int"}],"container-title":["Biomedicine & Aging Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210522014000288?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210522014000288?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T05:25:41Z","timestamp":1761888341000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2210522014000288"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["S2210522014000288"],"URL":"https:\/\/doi.org\/10.1016\/j.biomag.2014.03.003","relation":{},"ISSN":["2210-5220"],"issn-type":[{"type":"print","value":"2210-5220"}],"subject":[],"published":{"date-parts":[[2014,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of muscle invasive urinary bladders tumors: A potential role of the mTOR inhibitors","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Aging Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biomag.2014.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}